CorMedix (CRMD) EBITDA (2010 - 2025)

CorMedix has disclosed EBITDA across 16 years of filings, most recently posting -$84994.0 for Q4 2025.

• EBITDA for Q4 2025 came in at -$84994.0, down 4375.35% year-over-year; the trailing twelve-month figure through Dec 2025 was -$88000.0 (down 2833.33% YoY), and the FY2025 annual result was -$88000.0, down 2833.33% from the prior year.
• EBITDA came in at -$84994.0 for Q4 2025 at CorMedix, down from $8205.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of $8205.0 in Q3 2025 to a low of -$14.7 million in Q4 2023.
• The 5-year median for EBITDA is -$7.0 million (2022), against an average of -$5.2 million.
• Peak annual rise in EBITDA reached 142.11% in 2025, while the deepest fall reached 4375.35% in 2025.
• CorMedix's EBITDA stood at -$7.8 million in 2021, then retreated by 4.78% to -$8.2 million in 2022, then tumbled by 80.43% to -$14.7 million in 2023, then soared by 100.01% to $1988.0 in 2024, then slumped by 4375.35% to -$84994.0 in 2025.
• The last three EBITDA figures came in at -$84994.0 (Q4 2025), $8205.0 (Q3 2025), and -$5121.0 (Q2 2025), per Business Quant data.